adventtr
Morgan Stanley has downgraded STAAR Surgical (NASDAQ:STAA) to underweight, commenting that “Street expectations for meaningful growth acceleration in 2025/2026 seem unrealistic at this point.”
The investment bank said slower growth estimates in China mid-term “leave US HSD behind on 2026 sales, with consensus’ expectation of an acceleration up to teens growth, from MSD guide this year, as overly ambitious.”
Morgan Stanley also commented on recent reports that Alcon (ALC) could be interested in acquiring STAAR (STAA), stating that while “M&A is always an upside risk potential, it thinks likely margin dilution, tough for ALC, and lack of visibility in China makes for a lower risk here.”
It noted that neither company has commented on the M&A reports and that it had no knowledge of a potential deal.
Morgan Stanley set its price target at $37.
#Morgan #Stanley #cuts #STAAR #underweight #cites #growth #expectations #NASDAQSTAA
